calcipotriene and Eczema

Though topical corticosteroid is a standard treatment for chronic hand eczema (CHE), it can cause many adverse effects. Topical calcipotriol and monochromatic 308-nm excimer light (MEL) are new alternative therapies for several dermatoses, including CHE.. This study aims to compare the efficacy of the combination of MEL and topical calcipotriol versus topical calcipotriol alone.. One hand of the participants was randomly assigned to be irradiated with MEL twice weekly and topical calcipotriol applied twice daily while the other hand was assigned to receive only topical calcipotriol twice daily for 8 weeks. Then, only petrolatum ointment was applied during the 4-week follow-up period. Hand Eczema Severity Index (HECSI) and modified Total Lesion Symptom Score were assessed by a blinded investigator, and a visual analogue scale score of itching symptoms was graded by the participants.. In total, 36 hands from 18 subjects completed the protocol. On the combination-treated sides, the mean HECSI score was significantly reduced by 25% (p = 0.015) from the 4th week. Then, it was gradually decreased to 57 and 65% (p < 0.001) at the 8th week and at the follow-up visit, respectively. For the monotherapy-treated sides, the mean HECSI score was reduced to 41% (p = 0.001) and 49% (p < 0.001) at the 8th and 12th week, accordingly. At the end of the treatment period, itching scores were significantly decreased by around 64% (p < 0.001) and 51% (p = 0.002) on the combination-treated and the monotherapy-treated sides. No serious and persistent adverse reactions were found.. The combined MEL and topical calcipotriol may be considered as an alternatively effective treatment for CHE.

Topics: Administration, Topical; Adult; Aged; Calcitriol; Chronic Disease; Dermatologic Agents; Eczema; Female; Hand Dermatoses; Humans; Lasers, Excimer; Low-Level Light Therapy; Male; Middle Aged; Treatment Outcome

Topical potent corticosteroids are the mainstay of treatment for chronic hand eczema (CHE). However, there are numerous adverse effects associated with the chronic use of topical corticosteroids. Calcipotriol has been widely used in psoriasis and has been reported to achieve beneficial effects in several inflammatory diseases. This study aimed to evaluate the efficacy and safety of calcipotriol ointment compared to desoximetasone ointment in the treatment of CHE. Patch testing was performed in all recruited subjects. Then, each hand of the patient was randomly allocated for the application of either calcipotriol ointment or desoximetasone ointment twice daily for 8 weeks. Recurrence was assessed 4 weeks after discontinuation of the treatment. The Hand eczema severity index (HECSI) scores, quartile grading assessments and digital photographs were evaluated. Adverse reactions were also monitored. A total of 13 participants completed the protocol. Mean HECSI scores revealed up to a 75% reduction in both treatments (p < .001) without significant differences between the groups (p > .05). Approximately 70% of the subjects reported more than 75% improvement with calcipotriol at the end of the treatment. Mild scaling and mild dryness were the most common reactions found with calcipotriol and desoximetasone, respectively. In conclusion, calcipotriol ointment is safe and as effective as desoximetasone ointment. Calcipotriol ointment may be an alternative treatment option for CHE.

Topics: Administration, Cutaneous; Adult; Aged; Calcitriol; Chronic Disease; Dermatologic Agents; Desoximetasone; Double-Blind Method; Eczema; Female; Glucocorticoids; Hand Dermatoses; Humans; Male; Middle Aged; Ointments; Prospective Studies; Treatment Outcome

Atopic dermatitis (AD) is a common pruritic inflammatory skin disease characterized by impaired epidermal barrier function and dysregulation of Thelper-2 (T

Topics: Adaptive Immunity; Animals; Calcitriol; CD11 Antigens; Cell Count; Cytokines; Dendritic Cells; Dermatitis, Atopic; Dermatologic Agents; Disease Progression; Disease Susceptibility; Eczema; Feedback, Physiological; Homeostasis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Specific Pathogen-Free Organisms; Staphylococcal Skin Infections; Staphylococcus aureus; Th2 Cells

Topics: Aged; Betamethasone; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Eczema; Glucocorticoids; Humans; Male; Molluscum Contagiosum; Skin

Topics: Adult; Breast Diseases; Breast Neoplasms; Calcitriol; Dermatologic Agents; Diagnosis, Differential; Eczema; Female; Humans; Hyperpigmentation; Keratosis; Nipples; Paget's Disease, Mammary

Variably considered as a localized subtype of pustular psoriasis, palmoplantar pustulosis (PPP) is commonly treated with topical steroids, acitretin, and local phototherapy with oral or topical psoralen (PUVA). The utility of acitretin for PPP is limited by adverse effects such as myalgias and an extended risk of teratogenicity in female patients. Isotretinoin is a more tolerable retinoid with a shorter teratogenic window, but to date its effectiveness in PPP has not been reported. Herein we present two patients with PPP who responded well to isotretinoin treatment.. Two patients with PPP refractory to topical therapies were started on acitretin. Both patients developed adverse effects (including headache, myalgias, and mood alterations) leading to acitretin discontinuation. Isotretinoin monotherapy was started in one patient resulting in significant clearing of palmar plaques and scale, and the addition of isotretinoin to UVA therapy resulted in near-complete clearing of recalcitrant plantar plaques in the second patient.. Acitretin represents an important treatment for PPP, but is limited by adverse effects and extended teratogenicity. Our experience supports the utility of isotretinoin as a potential therapeutic alternative, which may be particularly beneficial in patients who are poor candidates for or unable to tolerate acitretin therapy.

Topics: Acitretin; Anti-Inflammatory Agents; Biopsy; Calcitriol; Ceramides; Cholesterol; Clobetasol; Combined Modality Therapy; Diagnostic Errors; Drug Combinations; Drug Substitution; Eczema; Emollients; Fatty Acids; Female; Humans; Isotretinoin; Male; Middle Aged; Psoriasis; Ultraviolet Therapy